March 19, 2026
The FDA has approved linerixibat (Lynavoy, GSK) for the treatment of cholestatic pruritus in adults with primary biliary cholangitis (PBC). Linerixibat is an oral ileal bile […]
March 19, 2026
The FDA has approved a new higher-dose version of injectable semaglutide (Wegovy HD, Novo Nordisk) for both weight loss and long-term weight-loss maintenance. The higher dose, […]
March 18, 2026
The FDA has approved icotrokinra (Icotyde, Johnson & Johnson), the first interleukin-23 (IL-23) oral targeted therapy for the treatment of moderate-to-severe plaque psoriasis, the manufacturer announced […]
March 16, 2026
The manufacturer of the interleukin-23 inhibitor tildrakizumab (Ilumya), Sun Pharma, announced today that the FDA has accepted its supplemental biologics license application for the indication of […]
March 16, 2026
A new Janus kinase inhibitor medication, deuruxolitinib (Leqselvi, Sun Pharma UK Limited), has been approved in the UK for the treatment of severe alopecia areata in […]
March 13, 2026
The European Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended updating the product information for the live attenuated chikungunya vaccine, Ixchiq (Valneva), to reflect […]
March 12, 2026
The National Institute for Health and Care Excellence (NICE) has recommended fezolinetant as the first non-hormonal treatment for menopausal hot flushes and night sweats for routine […]
March 11, 2026
Canadian federal health officials have issued a warning for clinicians administering IXCHIQ chikungunya vaccine in older, frail adults with comorbidities. “Healthcare professionals are advised to carefully […]
March 11, 2026
Patients aged 6 years and older with cystic fibrosis will be able to access the triple combination treatment vanzacaftor/tezacaftor/deutivacaftor on NHS Scotland after the Scottish Medicines […]